Growth Metrics

Ascendis Pharma A (ASND) Income from Continuing Operations: 2012-2024

Historic Income from Continuing Operations for Ascendis Pharma A (ASND) over the last 13 years, with Dec 2024 value amounting to -$409.2 million.

  • Ascendis Pharma A's Income from Continuing Operations rose 41.10% to -$62.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$236.4 million, marking a year-over-year increase of 47.15%. This contributed to the annual value of -$409.2 million for FY2024, which is 21.00% up from last year.
  • According to the latest figures from FY2024, Ascendis Pharma A's Income from Continuing Operations is -$409.2 million, which was up 21.00% from -$518.0 million recorded in FY2023.
  • Over the past 5 years, Ascendis Pharma A's Income from Continuing Operations peaked at -$409.2 million during FY2024, and registered a low of -$595.0 million during FY2022.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$518.0 million (2023), whereas its average is -$507.4 million.
  • Per our database at Business Quant, Ascendis Pharma A's Income from Continuing Operations slumped by 219,311.36% in 2020 and then increased by 21.00% in 2024.
  • Over the past 5 years, Ascendis Pharma A's Income from Continuing Operations (Yearly) stood at -$478.4 million in 2020, then grew by 8.27% to -$438.8 million in 2021, then tumbled by 35.60% to -$595.0 million in 2022, then increased by 12.94% to -$518.0 million in 2023, then climbed by 21.00% to -$409.2 million in 2024.